Advertisement

Outcomes Following Radical Cystectomy for Plasmacytoid Urothelial Carcinoma: Defining the Need for Improved Local Cancer Control

Published:November 16, 2016DOI:https://doi.org/10.1016/j.urology.2016.09.053

      Objective

      To evaluate oncological outcomes after radical cystectomy (RC) in patients with plasmacytoid urothelial carcinoma (UC) and to compare survival to that in patients with pure UC of the bladder.

      Materials and Methods

      We identified 46 patients with plasmacytoid UC and 972 with pure UC who were treated with RC between 1980 and 2009. All pathologic specimens were re-reviewed by a single GU pathologist. Patients were matched 1:2 by age, gender, Eastern Cooperative Oncology Group performance status, pathologic tumor stage, and nodal status to patients with pure UC. Survival was estimated using the Kaplan-Meier method and compared with the log rank test.

      Results

      Patients with plasmacytoid UC were more likely to have extravesical disease (≥pT3) (83% vs 43%, P < .0001) and positive margins (31% vs 2.1%, P < .0001) than patients with pure UC. Plasmacytoid UC was associated with decreased overall survival (27% vs 45% at 5 years, relative risk [RR] 1.4, P = .04), cancer-specific survival (36% vs 57% at 5 years, RR 1.7, P = .01), and local recurrence-free survival (63% vs 81% at 5 years, RR 2, P = .01). When patients with plasmacytoid UC were matched to those with pure UC, there were no significant differences in 5-year overall, cancer-specific, and local or distant recurrence-free survival.

      Conclusion

      Plasmacytoid UC is associated with a high rate of locally advanced disease and positive margins at RC, as well as increased local recurrence rates. Further research is necessary to delineate adjuvant or neoadjuvant treatment strategies to improve local cancer control of this rare subtype of UC.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sahin A.A.
        • Myhre M.
        • Ro J.Y.
        • et al.
        Plasmacytoid transitional cell carcinoma. Report of a case with initial presentation mimicking multiple myeloma.
        Acta Cytol. 1991; 35: 277-280
        • Zukerberg L.R.
        • Harris N.L.
        • Young R.H.
        Carcinomas of the urinary bladder simulating malignant lymphoma. A report of five cases.
        Am J Surg Pathol. 1991; 15: 569-576
        • Eble J.N.
        • Sauter G.
        • Epstein J.I.
        • Sesterhenn I.A.
        Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs. WHO Classification of Tumours.
        IARC Press, Lyon2004
        • Dayyani F.
        • Czerniak B.A.
        • Sircar K.
        • et al.
        Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis.
        J Urol. 2013; 189: 1656-1661
        • Fritsche H.M.
        • Burger M.
        • Denzinger S.
        • et al.
        Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases.
        J Urol. 2008; 180: 1923-1927
        • Kaimakliotis H.Z.
        • Monn M.F.
        • Cheng L.
        • et al.
        Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes.
        Urology. 2014; 83: 1112-1116
        • Keck B.
        • Wach S.
        • Stoehr R.
        • et al.
        Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy.
        BMC Cancer. 2013; 13: 71
        • Lopez-Beltran A.
        • Requena M.J.
        • Montironi R.
        • et al.
        Plasmacytoid urothelial carcinoma of the bladder.
        Hum Pathol. 2009; 40: 1023-1028
        • Raspollini M.R.
        • Sardi I.
        • Giunti L.
        • et al.
        Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series.
        Hum Pathol. 2011; 42: 1149-1158
        • Ricardo-Gonzalez R.R.
        • Nguyen M.
        • Gokden N.
        • et al.
        Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for intraperitoneal spread.
        J Urol. 2012; 187: 852-855
        • Ro J.Y.
        • Shen S.S.
        • Lee H.I.
        • et al.
        Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases.
        Am J Surg Pathol. 2008; 32: 752-757
        • Mai K.T.
        • Park P.C.
        • Yazdi H.M.
        • et al.
        Plasmacytoid urothelial carcinoma of the urinary bladder report of seven new cases.
        Eur Urol. 2006; 50: 1111-1114
        • Aldousari S.
        • Sircar K.
        • Kassouf W.
        Plasmacytoid urothelial carcinoma of the bladder: a case report.
        Cases J. 2009; 2: 6647
        • Kim S.P.
        • Frank I.
        • Cheville J.C.
        • et al.
        The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma.
        J Urol. 2012; 188: 405-409
        • Linder B.J.
        • Frank I.
        • Cheville J.C.
        • et al.
        Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis.
        J Urol. 2013; 189: 1670-1675
        • Wang J.K.
        • Boorjian S.A.
        • Cheville J.C.
        • et al.
        Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis.
        World J Urol. 2012; 30: 801-806
        • Al-Ahmadie H.A.
        • Iyer G.
        • Lee B.H.
        • et al.
        Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.
        Nat Genet. 2016; 48: 356-358